HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consumer Health Business News: Rebrands for Takeda OTC And Reckitt, DSM Acquires, Enzymatica Raises Funds

Executive Summary

A round-up of the latest consumer health industry news: Takeda completes the sale of its Japanese OTC business, which has rebranded as Alinamin; Reckitt drops the "Benckiser" from its name to signal new approach; Enzymatica looks to raise funds as COVID continues to bite; and Royal DSM expands its portfolio through a new deal with Amyris. 

You may also be interested in...



Amyris Announces Gen Z-Focused EcoFabulous As Latest Acquisition In $12m Portfolio Enrichment

Brands under development and recent acquisitions including EcoFabulous, Costa Brazil and Terasana will account for around 20% of overall 2021 revenue in Amyris’ Consumer business, according to the firm, which aspires to be the “L’Oreal of clean beauty.”

With ‘Significant Headroom For Growth,' Is Standalone Space Ahead For DSM Nutrition?

DSM says its nutrition segment, which includes human and animal nutrition and personal care, has a “unique business model combining 'global products' and 'local solutions'” and showed 6% organic sales growth for 2020 and 8% for Q4.

Stada Strikes Deal To Launch ViruProtect In Nordics

Stada to launch innovative common cold spray ViruProtect in four Nordic markets in 2021 after striking a new agreement with Sweden's Enzymatica.

Related Content

Topics

UsernamePublicRestriction

Register

RS151178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel